22ND CENTURY GROUP INC (XXII)
US90137F3010 - Common Stock
XXII gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 8 industry peers in the Tobacco industry. Both the profitability and financial health of XXII have multiple concerns. XXII has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year XXII has reported negative net income.
In the past year XXII has reported a negative cash flow from operations.
In the past 5 years XXII always reported negative net income.
In the past 5 years XXII always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -508.80%, XXII is doing worse than 87.50% of the companies in the same industry.
The Return On Invested Capital of XXII (106.52%) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -508.8% | ||
| ROE | N/A | ||
| ROIC | 106.52% |
ROA(3y)-214.42%
ROA(5y)-143.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XXII has a better Operating Margin (75.77%) than 100.00% of its industry peers.
XXII does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 75.77% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
XXII has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
XXII has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, XXII has more shares outstanding
Compared to 1 year ago, XXII has a worse debt to assets ratio.
2.2 Solvency
XXII has an Altman-Z score of -20.36. This is a bad value and indicates that XXII is not financially healthy and even has some risk of bankruptcy.
XXII has a Altman-Z score of -20.36. This is amonst the worse of the industry: XXII underperforms 87.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.36 |
ROIC/WACC19.09
WACC5.58%
2.3 Liquidity
XXII has a Current Ratio of 0.84. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.
XXII's Current ratio of 0.84 is on the low side compared to the rest of the industry. XXII is outperformed by 75.00% of its industry peers.
XXII has a Quick Ratio of 0.84. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.67, XXII perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.67 |
3. Growth
3.1 Past
XXII shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.98%.
XXII shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -71.08%.
Measured over the past years, XXII shows a small growth in Revenue. The Revenue has been growing by 4.03% on average per year.
EPS 1Y (TTM)4.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.39%
Revenue 1Y (TTM)-71.08%
Revenue growth 3Y4.64%
Revenue growth 5Y4.03%
Sales Q2Q%-66.06%
3.2 Future
The Earnings Per Share is expected to grow by 36.71% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -34.43% on average over the next years. This is quite bad
EPS Next Y82.92%
EPS Next 2Y36.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-58.25%
Revenue Next 2Y-34.43%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for XXII. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XXII. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, XXII is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.89 |
4.3 Compensation for Growth
XXII's earnings are expected to grow with 36.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.71%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for XXII!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22ND CENTURY GROUP INC
NASDAQ:XXII (11/22/2024, 8:14:42 PM)
After market: 0.0914 0 (-2.87%)0.0941
0 (-4.95%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.30M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -508.8% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 75.77% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.67 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)4.98%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y82.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-71.08%
Revenue growth 3Y4.64%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y